Evidence map›Paper›PMID 25771865›Full record

ArticleJournal of neurovirology2015

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.

Tuan Dong-Si, Sarah Gheuens, Amy Gangadharan, Made Wenten, Jeffrey Philip, James McIninch, Shoibal Datta, Nancy Richert, Carmen Bozic, Gary Bloomgren and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurovirology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Tuan Dong-SiDrug Safety and Risk Management, Biogen Idec Inc., 225 Binney Street, Cambridge, MA, 02142, USA.
Sarah GheuensDrug Safety and Risk Management, Biogen Idec Inc., 225 Binney Street, Cambridge, MA, 02142, USA. sarah.gheuens@biogenidec.com.
Amy GangadharanDrug Safety and Risk Management, Biogen Idec Inc., 225 Binney Street, Cambridge, MA, 02142, USA.
Made WentenDrug Safety and Risk Management, Biogen Idec Inc., 225 Binney Street, Cambridge, MA, 02142, USA.
Jeffrey PhilipData Sciences, Biogen Idec Inc., Cambridge, MA, USA.
James McIninchData Sciences, Biogen Idec Inc., Cambridge, MA, USA.
Shoibal DattaData Sciences, Biogen Idec Inc., Cambridge, MA, USA.
Nancy RichertNeurology Research and Development, Biogen Idec Inc., Cambridge, MA, USA.
Carmen BozicDrug Safety and Risk Management, Biogen Idec Inc., 225 Binney Street, Cambridge, MA, 02142, USA.
Gary BloomgrenDrug Safety and Risk Management, Biogen Idec Inc., 225 Binney Street, Cambridge, MA, 02142, USA.
Sandra RichmanDrug Safety and Risk Management, Biogen Idec Inc., 225 Binney Street, Cambridge, MA, 02142, USA.
Thomas WeberMarienkrankenhaus, Academic Teaching Hospital, University of Hamburg, Hamburg, Germany.
David B CliffordDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
Biogen (United States) · USUniversität Hamburg · DEWashington University in St. Louis · US

Funding

Washington University Network of Excellence in Neuroscience Clinical Trials SiteU10NS077384 · NINDS · WASHINGTON UNIVERSITY · PI CLIFFORD, DAVID B · 2011 to 2017
$1.9M
NEUROIMAGING AND NEUROBEHAVIORAL BASIS OF RISKY DECISION-MAKING IN ADOLESCENTSR01NR012907 · NINR · WASHINGTON UNIVERSITY · PI ANCES, BEAU M · 2011 to 2015
$1.9M
NINDS NIH HHS U10 NS077384NINR NIH HHS R01 NR012907
6 · The paper itself

Abstract

Natalizumab, a highly effective therapy for relapsing-remitting multiple sclerosis, is associated with a risk of progressive multifocal leukoencephalopathy (PML). The objective of this analysis was to examine factors predicting survival in a large natalizumab-associated PML global population. Patients with natalizumab-associated PML identified through postmarketing surveillance were followed up for up to 24 months using a structured questionnaire completed by treating physicians. Demographic and clinical characteristics, JC viral load, magnetic resonance imaging (MRI) results, and Expanded Disability Status Scale (EDSS) and Karnofsky Performance Scale (KPS) scores were compared in survivors and nonsurvivors. Kaplan-Meier analysis was used to model survival function. Among the 336 patients included in this analysis, 76 % survived, with mean follow-up time from PML diagnosis of 16.1 months for survivors; mean time from diagnosis to death was 4.7 months for nonsurvivors. Survivors were significantly younger at diagnosis, had significantly lower EDSS scores and higher KPS scores prior to PML diagnosis, and had significantly lower cerebrospinal fluid JC viral load at the time of diagnosis. Patients with less extensive disease on MRI at diagnosis had a higher survival rate than those with widespread disease. Survivors generally had less functional disability pre-PML, at PML diagnosis, and in subsequent months. In survivors, functional disability appeared to stabilize approximately 6 months post-PML diagnosis. In this analysis, younger age at diagnosis, less functional disability prior to PML diagnosis, lower JC viral load at diagnosis, and more localized brain involvement by MRI at the time of diagnosis appeared to predict improved survival in natalizumab-associated PML.

Indexed as

AdolescentAdultAgedBrainFemaleHumansImmunologic FactorsJC VirusKaplan-Meier EstimateLeukoencephalopathy, Progressive MultifocalMagnetic Resonance ImagingMaleMiddle AgedNatalizumabSurvivorsViral LoadImmunologic FactorsNatalizumabExpanded Disability Status ScaleKarnofsky Performance ScaleNatalizumabProgressive multifocal leukoencephalopathySurvival

Identifiers

PMID25771865
PMCPMC4628054
OpenAlexW1981265441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.